Jason Rhodes

Chair at Generation Bio

Jason Rhodes is a partner at Atlas Venture. Jason is the chairman and was the founding chief executive officer of Generation Bio, Dyne Therapeutics (NASDAQ: DYNE), and previously Disarm Therapeutics (acquired by Lilly in 2020). He is on the boards of Replimune (NASDAQ: REPL), Be Biopharma, Gemini Therapeutics, and Accent Therapeutics. Jason received his Bachelor of Arts degree from Yale University and his Master of Business Administration from the Wharton School of the University of Pennsylvania. He is a member of the advisory board of the Harvard Institute for RNA Medicine, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council.


  • Chair

    Current role


By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.